Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study
| Primer Autor |
Yusuf, Salim
|
| Co-autores |
Dagenais, Gilles R.
Leong, Darryl P.
Rangarajan, Sumathy
Lanas, Fernando
Lopez-Jaramillo, Patricio
Gupta, Rajeev
Diaz, Rafael
Avezum, Alvaro
Oliveira, Gustavo B. F.
Wielgosz, Andreas
Parambath, Shameena R.
Mony, Prem
Alhabib, Khalid F.
Temizhan, Ahmet
Ismail, Noorhassim
Chifamba, Jephat
Yeates, Karen
Khatib, Rasha
Rahman, Omar
Zatonska, Katarzyna
Kazmi, Khawar
Wei, Li
Zhu, Jun
Rosengren, Annika
Vijayakumar, K.
Kaur, Manmeet
Mohan, Viswanathan
Yusufali, AfzalHussein
Kelishadi, Roya
Teo, Koon K.
Joseph, Philip
|
| Título |
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study
|
| Editorial |
ELSEVIER SCIENCE INC
|
| Revista |
LANCET
|
| Lenguaje |
en
|
| Tipo de Recurso |
artículo original
|
| Derecho de Acceso |
restringido
|
| Description |
Agradecemos a Leanne Dyal, Chinthanie Ramasundarahettige y Dawn Agapay su ayuda durante la preparación del manuscrito. El estudio PURE es un estudio iniciado por investigadores y financiado por el Population Health Research Institute, el Hamilton Health Sciences Research Institute, los Canadian Institutes of Health Research (incluyendo la Estrategia para la Investigación Orientada al Paciente a través de la Unidad de Apoyo SPOR de Ontario), la Heart and Stroke Foundation (ON, Canadá), el Ministerio de Salud y Cuidados a Largo Plazo de Ontario, y por subvenciones sin restricciones de varias compañías farmacéuticas, con importantes contribuciones de AstraZeneca (Canadá), Sanofi-Aventis (Francia y Canadá), Boehringer Ingelheim (Alemania y Canadá), Servier Laboratories y GlaxoSmithKline, y contribuciones adicionales de Novartis, King Pharma y varias organizaciones nacionales y locales en los países participantes. Los detalles sobre la financiación, los países e instituciones participantes y el personal colaborador se muestran en el apéndice (pp. 20-25).
We would like to thank Leanne Dyal, Chinthanie Ramasundarahettige, and Dawn Agapay for their help throughout the preparation of the manuscript. The PURE study is an investigator-initiated study that is funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute, the Canadian Institutes of Health Research (including through the Strategy for Patient-Oriented Research via the Ontario SPOR Support Unit), the Heart and Stroke Foundation (ON, Canada), the Ontario Ministry of Health and Long-Term Care, and by unrestricted grants from several pharmaceutical companies, with major contributions from AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier Laboratories, and GlaxoSmithKline, and additional contributions from Novartis, King Pharma, and from several national and local organisations in participating countries. Details on the funding and participating countries and institutions, and on collaborating staff, are shown in the appendix (pp 20-25).
|
| doi |
10.1016/S0140-6736(19)32007-0
|
| Formato Recurso |
pdf
|
| Ubicación del archivo | |
| Disciplinas de la OCDE |
Medicina General e Interna
|
| Id de Web of Science |
WOS:000519536900035
|
| Access Rights |
restringido
|
| Derechos de acceso |
restringido
|
| Formato |
pdf
|
| Título de la cita (Recomendado-único) |
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study
|
| Identificador del recurso (Mandatado-único) |
artículo original
|
| Versión del recurso (Recomendado-único) |
version publicada
|
| ISSN |
0140-6736
|
| Tipo de ruta |
hibrida
verde
|
| Referencia del Financiador (Mandatado si es aplicable-repetible) |
PHRI
HHS
CIHR
Heart and Stroke
Ministry of Health and Long-Term Care
AstraZeneca (Canada)
Sanofi-Aventis (France and Canada)
Boehringer Ingelheim (Germany and Canada)
Servier Laboratories
GlaxoSmithKline
Novartis, King Pharma
|
- Colecciones
- Colección Publicaciones Científicas
cienciaabierta.ufro.cl
ciencia.abierta@ufrontera.cl